In the past week, the field of allogeneic CAR-T has heated up again due to the participation of Roche.

On November 26, Roche announced that it would acquire the biotech company Poseida for up to $1.5 billion. Poseida's R&D pipeline includes spot (allogeneic) CAR-T therapies in multiple therapeutic areas, covering hematological malignancies, solid tumors and autoimmune diseases.

Due to a series of factors such as cycle and cost, the commercialization process of autologous CAR-T has been subject to certain restrictions, so the industry has never stopped exploring allogeneic CAR-T. The market has high hopes for allogeneic CAR-T. Of course, this is not smooth sailing, because due to a series of factors such as effect, it will take some time for allogeneic CAR-T to break through.

Roche's investment in Poseida this time is mainly based on the latter's technology platform.

Poseida's non-viral platform is able to generate off-the-shelf CAR-T therapies rich in T memory stem cells, which the company believes can improve safety and efficacy.

Roche also highlighted Poseida's gene editing tools, including piggyBac insertion technology, which allows multiple CARs to be delivered in an efficient single-step manner without the need for a viral delivery system. Another Poseida technology allows for multiple gene knock-ins and knock-outs to prevent graft-versus-host and host-versus-graft reactions.

It is expected that with the participation of more large multinational companies, the breakthrough of allogeneic CAR-T will continue to accelerate.

https://mp.weixin.qq.com/